Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
نویسندگان
چکیده
BACKGROUND Ovarian cancer is a leading cause of cancer-related mortality. Although the disease is relatively rare, it carries a disproportionately large morbidity burden. OBJECTIVE We conducted a cost-utility analysis from a Canadian public payer perspective to determine the cost effectiveness of bevacizumab, a newly available treatment option for recurrent ovarian cancer. METHODS Using a 7-year time horizon, a three health-state cohort-based partitioned survival model was developed to assess the cost utility of bevacizumab plus chemotherapy (BEV) versus chemotherapy alone. We reconstructed individual patient data from published Kaplan-Meier curves. Clinical parameters, including progression-free survival and overall survival, were derived from the AURELIA phase III randomized controlled trial. Costs, resource utilization and utility values from recent Canadian sources were used to populate the model. Results were presented using incremental cost-utility ratios (ICURs). Uncertainty was examined through univariate and probabilistic sensitivity analyses. RESULTS The reconstructed individual patient data matched the AURELIA trial results. Total costs for the BEV and chemotherapy treatment arms were $Can79,086 and $Can54,982, respectively. Total estimated quality-adjusted life-years (QALYs) were 1.1055 and 0.9926 for the BEV and chemotherapy arms, respectively. The ICUR was estimated to be $Can213,424 per QALY gained. At a willingness-to-pay threshold of $Can100,000 per QALY gained, the probability of BEV being cost effective was 0. CONCLUSIONS The results of our analysis suggest that the addition of bevacizumab to single-agent chemotherapy treatment, while improving patient outcomes, is unlikely to be cost effective in this Canadian patient population. The results also provide some preliminary validation for use of individual patient data-reconstruction techniques in pharmacoeconomic evaluation.
منابع مشابه
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
Patients with platinum-resistant ovarian cancer have progression of disease within 6 months of completing platinum-based chemotherapy. While several chemotherapeutic options exist for the treatment of platinum-resistant ovarian cancer, the overall response to any of these therapies is ~10%, with a median progression-free survival of 3-4 months and a median overall survival of 9-12 months. Bevac...
متن کاملPalliative systemic therapy for women with recurrent epithelial ovarian cancer: current options
OBJECTIVES To review the available systemic treatments for women with recurrent ovarian cancer. METHODS A literature review was conducted for recurrent ovarian cancer articles in English, including randomized trials, Phase II trials, or reviews. RESULTS We discuss the efficacy and toxicity outcomes associated with systemic therapy for platinum-sensitive and platinum-resistant ovarian cancer...
متن کاملCritical appraisal of bevacizumab in the treatment of ovarian cancer
Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy for first-line treatment of advanced ovarian cancer. Additional Phase III trials evaluated bevac...
متن کاملGeneration of Cisplatin-Resistant Ovarian Cancer Cell Lines
Ovarian cancer is the most lethal gynecological cancer in which cisplatin-based treatment plays fundamental role as the first line chemotherapy option. However, development of platinum-resistance is a critical and poorly understood problem in ovarian cancer treatment. Although in vitro generation of platinum-resistant ovarian cancer cell lines is a long established approach to uncover the molec...
متن کاملترکیب جم سیتابین- کربوپلاتین در درمان عود سرطان تخمدان: یک مطالعه آیندهنگر
Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 !mso]> st1":*{behavior:url(#ieooui) } /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tst...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2018